Skip to main content
Fig. 6 | Clinical Epigenetics

Fig. 6

From: Aberrant JAK-STAT signaling-mediated chromatin remodeling impairs the sensitivity of NK/T-cell lymphoma to chidamide

Fig. 6

The JAK inhibitors tofacitinib and ruxolitinib reverse chidamide resistance by altering chromatin remodeling. A Hierarchical clustering showing the DEGs in HANK1 cells treated with tofacitinib or ruxolitinib versus DMSO (p < 0.05, |log2-fold change|> 1). B GSEA pathways analysis of the JAK-STAT pathway after tofacitinib or ruxolitinib treatment versus DMSO treatment of HANK1 cells. C The JAK inhibitors tofacitinib and ruxolitinib impaired the JAK-STAT pathway in resistant NKTL. D RT–qPCR validation of genes in the JAK-STAT pathway for sensitive cells and resistant cells with or without tofacitinib/ruxolitinib treatment. E ChIP-qPCR of genes in the JAK-STAT pathway for sensitive cells and resistant cells with or without tofacitinib/ruxolitinib treatment. HANK1/SNK6 cells were treated with tofacitinib/ruxolitinib or DMSO. The results are expressed as the mean ± SD of three independent experiments. *p < 0.05, n.s., not significant

Back to article page

Clinical Epigenetics

ISSN: 1868-7083

Contact us